Grindr reported on November 18 that huadong medicine (000963.SZ) stated on the investor interaction platform that the orally ingested small molecule GLP-1 receptor agonist HDM1002, independently developed by the company, obtained the topline results of Phase II clinical research for weight management indications in October 2024. The company plans to submit a pre-Phase III communication application in Q4 of 2024 and expects to conduct Phase III clinical trials for weight management indications in Q1 of 2025. Semaglutide injection for diabetes indications has completed the inclusion of all subjects in the Phase III clinical research and is expected to obtain key endpoint data in Q4 of 2024 and submit a pre-BLA communication.
华东医药(000963.SZ)：司美格鲁肽注射液糖尿病适应症已完成III期临床研究全部受试者入组，预计2024年Q4获得主要终点数据并递交pre-BLA沟通
huadong medicine (000963.SZ): Simiglucagon injection for diabetes indications has completed the enrollment of all subjects in Phase III clinical trials, and is expected to obtain primary endpoint data in Q4 2024 and submit pre-BLA communication.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated